Resources Investment Advisors LLC. lowered its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 7.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,992 shares of the biopharmaceutical company’s stock after selling 490 shares during the quarter. Resources Investment Advisors LLC.’s holdings in Halozyme Therapeutics were worth $229,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of HALO. CWM LLC lifted its holdings in Halozyme Therapeutics by 123.2% during the first quarter. CWM LLC now owns 848 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 468 shares during the period. Belpointe Asset Management LLC purchased a new stake in Halozyme Therapeutics during the fourth quarter worth $50,000. Harbour Investments Inc. purchased a new stake in Halozyme Therapeutics during the fourth quarter worth $51,000. Quadrant Capital Group LLC lifted its holdings in Halozyme Therapeutics by 111.5% during the fourth quarter. Quadrant Capital Group LLC now owns 960 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 506 shares during the period. Finally, Harvest Fund Management Co. Ltd purchased a new stake in Halozyme Therapeutics during the fourth quarter worth $57,000. Hedge funds and other institutional investors own 92.93% of the company’s stock.
Insider Buying and Selling
In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $42.41, for a total value of $424,100.00. Following the completion of the transaction, the senior vice president now directly owns 151,911 shares of the company’s stock, valued at $6,442,545.51. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 80,000 shares of company stock valued at $3,345,700 over the last quarter. 2.40% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
Halozyme Therapeutics Trading Up 0.7 %
Halozyme Therapeutics stock opened at $42.24 on Friday. The company has a quick ratio of 5.44, a current ratio of 6.58 and a debt-to-equity ratio of 9.91. Halozyme Therapeutics, Inc. has a 52 week low of $29.85 and a 52 week high of $59.46. The company has a market capitalization of $5.57 billion, a price-to-earnings ratio of 24.70, a price-to-earnings-growth ratio of 0.64 and a beta of 1.24. The stock has a 50-day moving average price of $39.95 and a 200 day moving average price of $38.79.
Halozyme Therapeutics Profile
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
- Five stocks we like better than Halozyme Therapeutics
- How to Build Wealth with the Dividend Aristocrat Index
- Can These 2 Industrial Titans Extend Double-Digit YTD Growth?
- Roth IRA Calculator: Calculate Your Potential Returns
- How to Profit from These 3 Membership Club Stocks’ Strengths
- Do ETFs Pay Dividends? What You Need to Know
- 5 Best High-Yield Dividend Stocks for Any Economic Climate
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.